

Thursday, March 15, 2018
9:00 am – 10:20 pm (Eastern)

I. Amendment Review— Update 07

A091401, Randomized Phase II Study Of Nivolumab With Or Without Ipilimumab In Patients With Metastatic Or Unresectable Sarcoma (Protocol Version Date 02/12/18)

II. Continuing Review

A041501, A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (A Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL (Protocol Version Date 01/23/18)

III. Continuing Review

NCIC MA.32, A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer (Protocol Version Date 02/04/16)

IV. Continuing Review

S1416, Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer with or Without Brain Metastases (Protocol Version Date 10/18/17)

V. Continuing Review

S1507, A Phase II Trial of Trametinib with Docetaxel in Patients with Kras Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies (Protocol Version Date 01/04/17)
